cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Portage Biotech Inc
2 own
1 watching
Current Price
$0.24
$0.02
(8.6%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
65.04M
52-Week High
52-Week High
4.40000
52-Week Low
52-Week Low
0.20000
Average Volume
Average Volume
0.07M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization65.04M
icon52-Week High4.40000
icon52-Week Low0.20000
iconAverage Volume0.07M
iconDividend Yield--
iconP/E Ratio--
What does the Portage Biotech Inc do?
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company s product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Read More
News & Events about Portage Biotech Inc.
Globe Newswire
9 months ago
WESTPORT, Conn., June 26, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, announced today that it has dosed the first patient in its Phase 1a trial, ADPORT-601...
Insider
1 year ago
The Food and Drug Administration approved Zavzpret, a nasal spray from Pfizer, on Friday. The medication is expected to hit shelves this July. Pfizer is releasing a new migraine drug.Carlo Allegri/Reuters The Food and Drug Administration on Friday approved a new nasal spray to treat migraines. The ...
Globe Newswire
1 year ago
WESTPORT, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Companys management team will be presenting virtually at ...
Globe Newswire
1 year ago
- Enrollment ongoing in IMPORT-201 Phase 1/2 trial of PORT-2 in Melanoma and Non-Small Cell Lung Cancer - Company on track to initiate Phase 1 portion of ADPORT-601 trial by end of 2Q23 - Company to Host a Key Opinion Leader Event on Targeting Adenosine Pathway in Cancer WESTPORT, Conn., March 01, ...
Globe Newswire
1 year ago
WESTPORT, Conn., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Companys management team will participate in a fireside chat...
Frequently Asked Questions
Frequently Asked Questions
What is Portage Biotech Inc share price today?
plus_minus_icon
Can Indians buy Portage Biotech Inc shares?
plus_minus_icon
How can I buy Portage Biotech Inc shares from India?
plus_minus_icon
Can Fractional shares of Portage Biotech Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Portage Biotech Inc stocks?
plus_minus_icon
What is today’s traded volume of Portage Biotech Inc?
plus_minus_icon
What is today’s market capitalisation of Portage Biotech Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Portage Biotech Inc?
plus_minus_icon
What percentage is Portage Biotech Inc down from its 52-Week High?
plus_minus_icon
What percentage is Portage Biotech Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$0.24
$0.02
(8.6%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Foreside Fund Services acts as the distributor to the DriveWealth ICE 100 Index ETF and is not affiliated with Borderless Investing Inc, DriveWealth LLC, BlackOak Investors LP, ACR Group, or other entities referenced on this website.

              Get Started with as little as $1.00